Pauling.AI

Exciting News for Pauling AI! ?? We are proud to announce that Pauling AI has officially been Certified as a Vitalist Organization by the Vitalism Foundation! At Pauling AI, our mission is to revolutionize computational chemistry to accelerate drug discovery and make new therapies more accessible and affordable. We’re dedicated to using cutting-edge technology to bring new therapies to market faster, helping people live longer, healthier lives. Our work aligns deeply with the Vitalist ideals—advancing science and engineering to push the boundaries of what’s possible for human lifespan. This certification is a testament to our commitment to making real progress in the fight against aging. As Javier puts it: “Vitalism reflects a basic human desire—to live longer. Organizations working in drug discovery have a responsibility to embrace this mission and accelerate scientific progress for everyone’s benefit.” Over the past few months, we’ve achieved exciting milestones, including key partnerships in the longevity space and advancements in our platform to automate computational chemistry. We’re just getting started, and with the support of the Vitalist ecosystem, we’re more motivated than ever to help shape the future of life sciences. ?? Learn more about our certification and mission at:?https://lnkd.in/g-NX8c-R

Pablo joined us a few months ago, but we didn't get the chance to introduce him yet: Pablo Villanueva is our latest colleague to join?Pauling.AI. He has degrees in Mathematics and Computer Engineering. In addition to working at Pauling full time he is also pursuing a Master's degree in Artificial Intelligence and Quantum Computing. He joined us as an intern in July 2024 and since October he has been working full-time as a Software Engineer. Like all of us he is very excited about the potential of AI to make drug discovery faster and cheaper and to use technology to find new medicines.

We're #hiring a new Software Engineer. See the job posting below and let us know if you or someone you know would be a great fit: Pauling is building a new platform for drug discovery. We are using state of the art AI, large language models and physics based simulation to help scientists find new molecules in days instead of years. Our team comes from top technology companies such as Microsoft and Google and some of the leading universities in the world. We are VC funded and have advisors from world leading research institutions and pharma companies. We are a fast moving, results driven company. Engineering-founded and engineering-led. We care about our mission to make drug discovery radically easier and cheaper, help cure diseases and extend human lifespan. Come join us. We are looking for a software engineer. We use mostly Python. Some of the work that you will be participating includes: * Large scale data processing pipelines. Normally using Dataflow in Google Cloud * Frontend development for scientific tools * LLM fine tuning, and development of agentic systems * Training AI models for biological and chemical data We have a fully distributed team around the world. All of us work remotely but meet often. For the right person this will be an ideal opportunity to do interesting and meaningful work, grow personally and professionally and do something that matters to humanity.

?? Exciting News at Pauling.AI! ?? We are thrilled to announce that Flex Capital has joined our seed round investment! This partnership marks a significant milestone in our journey, and we couldn't be more grateful for their support and confidence in our vision. Thank you to Auren and the Flex Capital team for believing in our mission to improve drug discovery. Here's to a future of groundbreaking achievements together! https://lnkd.in/gz--R29p

Today I'm very glad to announce that Pauling.AI will participate in the next Frequency Bio cohort, hosted by Pillar VC. I'm looking forward to join a great group of biotech entrepreneurs and scientists in a few weeks!

Very excited to attend the Longevity Biotech Fellowship and Foresight Institute workshop on bottlenecks to solve aging in a few weeks. And also to meet old and new friends at Stanford and FutureHouse. Mark Hamalainen Mari?lle van Kooten Anastasia Egorova Michael Florea Matthew "Oki" O'Connor Dr. Emil Kendziorra Jonathan Gootenberg Kevin Perrott PhD - Vitalist and many others. https://lnkd.in/g76GmncJ

Today I wanted to share a bit of good news. Pauling.AI has been accepted into the NVIDIA Inception program! The NVIDIA Inception program is designed to support startups by providing technical guidance, go-to-market support, and access to a global network of experts. Recently, NVIDIA has intensified its focus on life sciences, harnessing the power of AI and high-performance computing to revolutionize healthcare and biotechnology. This presents a remarkable opportunity for Pauling.AI and we are very excited to participate in NVIDIA's Inception program.

We've known of several therapies to extend healthy lifespan in animals for quite some time, including rapamycin, senolytics and others. But an important question is, why haven't these therapies made it from the lab to the clinic and to people? One reason is that they have never been proved in a clinical trial to actually extend lifespan in humans. Because nobody has ever paid to run such a trial. Unfortunately the economic reality of drug development is that taking a drug to market costs tens, if not hundreds of millions of dollars. So, the only drugs that are developed are the ones that can recover these costs. Which means drugs that are under patent protection. I believe the most promising path to get to therapies for longevity is new molecules, which can be patented, for diseases other than aging. But with reasonable evidence or data that shows impact in aging. Possibly following similar mechanisms to current therapies, but sold at much higher prices. I don't think over the next few years we will see fancy new partial reprogramming drugs, or gene therapies. But hopefully we will have rapalogs, senolytics and small molecule immunomodulators. And that may give us a few more years to continue working on the exciting stuff.

Baselines matter! In this post from Inductive Bio they show how picking a better baseline for docking the results are very comprable to AlphaFold3. The original AlphaFold3 compared against Vina, which is very popular, but not really close to state of the art. Still, we're very interested to see what new features AlphaFold3 will bring to the insilico methods in drug discovery. https://lnkd.in/eEtx8UWN

Over the next few weeks we will share a bit about what we are doing at Pauling. Today I wanted to introduce our Chief Scientific Officer, Oleksandr Savytskyi, PhD. Oleksandr is expert in computational drug discovery, molecular modeling, virtual screening, molecular dynamics simulations and high-performance computing (grid/cloud). He has 15 years of experience in pre-clinical research. He completed a PhD in Molecular Biology in 2017 and the results of his work were awarded several national and international prizes. For example, the "State Prize of the President of Ukraine for Young Scientists" in 2018, 'Kyiv City Mayor Prize" in 2018, "Platon Kostyuk Award 2018, which is provided by the Shevchenko Scientific Society, Inc (New York, USA)". Oleksandr?completed a Postdoctoral Research Fellow position at Mayo Clinic (USA) in 2023 and since 2024 has started a new role as?Chief Scientific Officer (CSO) at Pauling.AI.